-
Mashup Score: 0Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN) - Blood Cancer Journal - 11 month(s) ago
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, male-predominant hematologic malignancy with poor outcomes and with just one recently approved agent (tagraxofusp). It is characterized by the abnormal proliferation of precursor plasmacytoid dendritic cells (pDCs) with morphologic and molecular similarities to acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)/chronic…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 66Comprehensive Review of AL amyloidosis: some practical recommendations - Blood Cancer Journal - 2 year(s) ago
Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell (PC) clone and the secretion of unstable immunoglobulin-free light chains (FLC) that infiltrate peripheral tissues and result in detrimental end-organ damage. Disease presentation is rather vague, and the hallmark of…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @VincentRK: A great review on the diagnosis and management of AL amyloidosis. #OpenAccess #BCJ @Mohty_EBMT https://t.co/wtUTFjgIBB https…
-
-
Mashup Score: 13CAR-T cell therapy: current limitations and potential strategies - Blood Cancer Journal - 2 year(s) ago
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
CAR-T therapy. Current limitations and strategies to overcome. Review Article. #OpenAccess #BCJ https://t.co/qmjW5GaqU0 https://t.co/ejCpe1VhlN
-
-
Mashup Score: 5
When clonal plasma cells grow at anatomic sites distant from the bone marrow or grows contiguous from osseous lesions that break through the cortical bone, it is referred to as extramedullary multiple myeloma (EMD). EMD remains challenging from a therapeutic and biological perspective. The pathogenetic mechanisms are not completely understood and it is generally associated with high-risk…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
Extra medullary disease in multiple myeloma. Review article. #OpenAccess #BCJ @myelomaMD @MayoCancerCare @MayoClinic @BloodCancerJnl https://t.co/xMxhpyiB18
-
-
Mashup Score: 1
Multiple myeloma (MM) represents approximately 15% of haematological malignancies and most of the patients present with bone involvement. Focal or diffuse spinal osteolysis may result in significant morbidity by causing painful progressive vertebral compression fractures (VCFs) and deformities. Advances in the systemic treatment of myeloma have achieved high response rates and prolonged the…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
Role of cement augmentation w/ percutaneous vertebroplasty & balloon kyphoplasty for the Tx of vertebral compression fractures in multiple myeloma: IMWGconsensus statement [Feb 26, 2019] Kyriakou et al. #BCJ https://t.co/p738lVYNzt #mmsm #oncorad #openaccess
-
-
Mashup Score: 4Treatment and outcomes of POEMS syndrome: changes in the past 20 years - Blood Cancer Journal - 3 year(s) ago
Blood Cancer Journal –
Treatment and outcomes of POEMS syndrome: changes in the past 20… Source: Blood Cancer JournalCategories: Hematologists1, Latest HeadlinesTweet-
RT @BloodCancerJnl: Treatment and outcome of POEMS syndrome. #mmsm #BCJ https://t.co/p4N4s8FHxO https://t.co/Pnr2xBF44m
-
-
Mashup Score: 7Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies - Blood Cancer Journal - 3 year(s) ago
This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) correlated with anti-Spike (S) IgG d42 titers (Spearman r = 0.865, p < 0.0001), and an anti-S IgG d42 level ≥3100 UA/mL was predictive of NAb ≥ 30%, the positivity cutoff for NAb (p < 0.0001). Only 47% of the patients...
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
Reduced immune responses in hematologic malignancies. Only half the patients appear to generate sufficient immune protection. Especially if on B cell targeting treatments. #BCJ @BloodCancerJnl @Mohty_EBMT https://t.co/Bt4r1uQ7hv
-
-
Mashup Score: 3Drug importation: limitations of current proposals and opportunities for improvement - Blood Cancer Journal - 3 year(s) ago
Drug importation is a policy proposal to help alleviate rising pharmaceutical prices. Restrictions on drug importation stem from the Federal Food, Drug, and Cosmetic Act but authorization of importation can be made by the Health and Human Services (HHS) Secretary. During the Trump administration a number of states passed laws to develop a drug importation programs, however, none have been…
Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
Prescription drug costs in America: We discuss the limitations of current proposals and opportunities for improvement of prescription drug importation. @BloodCancerJnl #BCJ #OpenAccess https://t.co/gFjYKFCIPA
-
-
Mashup Score: 3The Multiple Myeloma Daily - 3 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Multiple Myeloma Daily! https://t.co/F4VshTi2BI Thanks to @VincentRK #bcj #thalomid
-
-
Mashup Score: 2
Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from… Source: Blood Cancer JournalCategories: Hem/Oncs, Latest HeadlinesTweet-
A striking result from a new myeloma study from CONNECT registry: Myeloma treatments have similar anti tumor efficacy across different age groups as evidenced by the time to progression curves. #BCJ @BloodCancerJnl @rabonour1 https://t.co/NHKTthUc5N https://t.co/XzG9KmVBIi
-
Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN) [Dec 6, 2019] Beird et al. @Malfayez7 @JoeKhouryMD @doctorpemm #BCJ https://t.co/92ePiDNokE #BPDCN #openaccess